SML1496

Buformin hydrochloride

≥98% (HPLC)

• 別名: 1-Butylbiguanide hydrochloride, N-Butyl-imidodicarbonimidic diamide hydrochloride
• 実験式（ヒル表記法）: C₆H₁₅N₅ · HCl
• CAS番号: 1190-53-0
• 分子量: 193.68
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• 形状: powder
• 色: white to beige
• 溶解性: H₂O: 25 mg/mL, clear
• 保管温度: −20°C
• InChI: 1S/C6H15N5.ClH/c1-2-3-4-10-6(9)11-5(7)8;/h2-4H2,1H3,(H6,7,8,9,10,11);1H
• InChI Key: KKLWSPPIRBIEOV-UHFFFAOYSA-N

詳細

アプリケーション

Buformin hydrochloride has been used as an internal standard in liquid chromatography-tandem mass spectrometry to analyze postmortem distribution/redistribution of buformin in body fluids and solid tissues in an autopsy case.

生物化学的／生理学的作用

Buformin is an oral antidiabetic drug with antiproliferative properties; AMPK activator. Buformin, an antidiabetic biguanide drug, was withdrawn as an antidiabetic drug in several countries because of the side effect of lactic acidosis, but is now being investigated as an anticancer agent. Buformin inhibits the growth and development of cancer. Buformin has been shown to postpone spontaneous carcinogenesis as well as inhibit induced carcinogenesis in animal studies. Buformin decreased cancer incidence, multiplicity, and burden in a rat study of chemically induced mammary carcinogenesis. Buformin also reduced renal cell carcinoma survival under conditions of glucose deprivation. Buformin′s anticancer activity is thought to involve disruption of the Warburg effect by AMPK activation, which decreases hepatic glucose production, and inhibition of the mTor pathway.

安全性情報

• ピクトグラム: GHS05,GHS07
• シグナルワード: Danger
• 危険有害性情報: H302,H315,H318,H335
• 注意書き: P261 - P264 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338
• 危険有害性の分類: Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
• ターゲットの組織: Respiratory system
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable